[{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molibresib","moa":"||Bromodomain and extra-terminal motif (BET)","graph1":"Oncology","graph2":"Preclinical","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Calidi Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"||ErbB-2\/ErbB-3 heterodimer","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ Undisclosed"},{"orgOrder":0,"company":"Chinese Academy of Medical Sciences","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Chinese Academy of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese Academy of Medical Sciences \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Chinese Academy of Medical Sciences \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Children's Cancer Group, China","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Cancer Group, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Cancer Group, China \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Children's Cancer Group, China \/ Undisclosed"},{"orgOrder":0,"company":"Children's Cancer Group, China","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Cancer Group, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Cancer Group, China \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Children's Cancer Group, China \/ Undisclosed"},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"National Cancer Centre, Singapore | KK Women's and Children's Hospital | Australia New Zealand Gynaecological Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National University Hospital, Singapore \/ National Cancer Centre, Singapore | KK Women's and Children's Hospital | Australia New Zealand Gynaecological Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"National University Hospital, Singapore \/ National Cancer Centre, Singapore | KK Women's and Children's Hospital | Australia New Zealand Gynaecological Oncology Group"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"Korean Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catholic University of Korea \/ Korean Cancer Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Catholic University of Korea \/ Korean Cancer Study Group"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"iOMEDICO | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIO-Studien-gGmbH \/ iOMEDICO | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"AIO-Studien-gGmbH \/ iOMEDICO | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Pierre Fabre","highestDevelopmentStatusID":"8","companyTruncated":"University of Aarhus \/ Pierre Fabre"},{"orgOrder":0,"company":"Centre Oscar Lambret","sponsor":"Pierre Fabre | National Cancer Institute, France","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Centre Oscar Lambret","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Oscar Lambret \/ Pierre Fabre | National Cancer Institute, France","highestDevelopmentStatusID":"8","companyTruncated":"Centre Oscar Lambret \/ Pierre Fabre | National Cancer Institute, France"},{"orgOrder":0,"company":"ARCAGY GINECO GROUP","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"ARCAGY GINECO GROUP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ARCAGY GINECO GROUP \/ Pierre Fabre","highestDevelopmentStatusID":"8","companyTruncated":"ARCAGY GINECO GROUP \/ Pierre Fabre"},{"orgOrder":0,"company":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori \/ Pierre Fabre","highestDevelopmentStatusID":"8","companyTruncated":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori \/ Pierre Fabre"},{"orgOrder":0,"company":"SOLTI Breast Cancer Research Group","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"SOLTI Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOLTI Breast Cancer Research Group \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"SOLTI Breast Cancer Research Group \/ Pierre Fabre"},{"orgOrder":0,"company":"Spanish Lung Cancer Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Spanish Lung Cancer Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spanish Lung Cancer Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spanish Lung Cancer Group \/ Undisclosed"},{"orgOrder":0,"company":"Wales Cancer Trials Unit","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Wales Cancer Trials Unit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wales Cancer Trials Unit \/ Pierre Fabre","highestDevelopmentStatusID":"8","companyTruncated":"Wales Cancer Trials Unit \/ Pierre Fabre"},{"orgOrder":0,"company":"Johannes Gutenberg University Mainz","sponsor":"Pierre Fabre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Johannes Gutenberg University Mainz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johannes Gutenberg University Mainz \/ Pierre Fabre","highestDevelopmentStatusID":"8","companyTruncated":"Johannes Gutenberg University Mainz \/ Pierre Fabre"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Research Group - Collaborative Group, Beirut, Lebanon.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LEBANON","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Cancer Research Group - Collaborative Group, Beirut, Lebanon.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Research Group - Collaborative Group, Beirut, Lebanon. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cancer Research Group - Collaborative Group, Beirut, Lebanon. \/ Undisclosed"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Mirati Therapeutics | Phase One Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Mirati Therapeutics | Phase One Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Mirati Therapeutics | Phase One Foundation"},{"orgOrder":0,"company":"University of Miami","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Miami \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"University of Miami \/ Genentech"},{"orgOrder":0,"company":"The Netherlands Cancer Institute","sponsor":"Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"The Netherlands Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Netherlands Cancer Institute \/ Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell","highestDevelopmentStatusID":"8","companyTruncated":"The Netherlands Cancer Institute \/ Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda C\u00e0 Granda | Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Cl\u00ednico de Valencia | University of Campania Luigi Vanvitell"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Adrienne G. Waks","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vinorelbine Tartrate","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Adrienne G. Waks","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Adrienne G. Waks"}]
Find Clinical Drug Pipeline Developments & Deals for Vinorelbine Tartrate
Details :
Zenocutuzumab (MCLA-128) in combination with trastuzumab and vinorelbine in patients met primary endpoint of Clinical Benefit Rate at 24 weeks and showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1.
Details :
The two drugs are tubulin inhibitor, vinorelbine, approved by the U.S. Food and Drug Administration (FDA) and available in clinics, and bromodomain inhibitor, I-BET-762, FDA approved for clinical trials.
Details :
Vinorelbine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhabdomyosarcoma.
Details :
Vinorelbine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Sponsor :
Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda Cà Granda | Fundación para la Investigación del Hospital Clínico de Valencia | University of Campania Luigi Vanvitell
Details :
Vinorelbine Tartrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colonic Neoplasms.
Sponsor :
Vall d'Hebron Institute of Oncology | Agendia | European Organisation for Research and Treatment of Cancer | Azienda Ospedaliera Niguarda Cà Granda | Fundación para la Investigación del Hospital Clínico de Valencia | University of Campania Luigi Vanvitell
Details :
Vinorelbine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large-Cell, Anaplastic.
Details :
Vinorelbine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Details :
Vinorelbine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large-Cell, Anaplastic.
Details :
Vinorelbine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Details :
Vinorelbine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Reset All
